B K Keppler Selected Research

Neoplasms (Cancer)

1/2023	Corrigendum to: Recent Developments in the Field of Tumor-Inhibiting Metal Complexes.
2/2017	Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance.
5/2016	Multi-scale imaging of anticancer platinum(iv) compounds in murine tumor and kidney.
5/2015	Triapine-mediated ABCB1 induction via PKC induces widespread therapy unresponsiveness but is not underlying acquired triapine resistance.
1/2015	Improved reaction conditions for the synthesis of new NKP-1339 derivatives and preliminary investigations on their anticancer potential.
8/2009	Ribonucleotide reductase as one important target of [Tris(1,10-phenanthroline)lanthanum(III)] trithiocyanate (KP772).
1/2009	Inhibitory Effects of the Ruthenium Complex KP1019 in Models of Mammary Cancer Cell Migration and Invasion.
6/2007	Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24).
12/2005	Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors--a CESAR study (Central European Society for Anticancer Drug Research--EWIV).
2/2005	Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

B K Keppler Research Topics

Disease

16	Neoplasms (Cancer) 01/2023 - 01/2000
3	Breast Neoplasms (Breast Cancer) 01/2009 - 01/2005
2	Colorectal Neoplasms (Colorectal Cancer) 02/2017 - 02/2005
2	Neoplasm Metastasis (Metastasis) 01/2009 - 01/2003
1	Bile Duct Neoplasms (Bile Duct Cancer) 03/2024
1	Hypersensitivity (Allergy) 02/2017
1	Leukemia 05/2015
1	Burns 01/2005
1	Vomiting 01/2005
1	Wounds and Injuries (Trauma) 01/2005
1	Sepsis (Septicemia) 01/2005
1	Carcinoma (Carcinomatosis) 01/2003

Drug/Important Bio-Agent (IBA)

7	RutheniumIBA 01/2015 - 01/2000
4	Cisplatin (Platino)FDA LinkGeneric 02/2017 - 01/2001
4	IndazolesIBA 01/2015 - 01/2000
4	indazolium trans- (tetrachlorobis(1H- indazole)ruthenate (III))IBA 01/2009 - 01/2003
2	KP 1339IBA 03/2024 - 02/2005
2	Coordination ComplexesIBA 01/2023 - 01/2003
2	PlatinumIBA 05/2016 - 01/2003
2	ProdrugsIBA 05/2016 - 01/2003
2	DNA (Deoxyribonucleic Acid)IBA 08/2009 - 04/2001
2	Proteins (Proteins, Gene)FDA Link 06/2007 - 01/2005
2	Cytostatic AgentsIBA 02/2005 - 04/2001
2	LigandsIBA 08/2001 - 01/2000
2	NitrogenIBA 08/2001 - 01/2000
2	Ruthenium CompoundsIBA 04/2001 - 03/2001
2	tetrachlorobis(indazole)ruthenate(III)IBA 03/2001 - 01/2000
1	TrabectedinIBA 02/2017
1	3-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine)IBA 05/2015
1	Antineoplastic Agents (Antineoplastics)IBA 06/2007
1	LanthanumIBA 06/2007
1	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 06/2007
1	tris(8-quinolinolato)gallium (III)IBA 12/2005
1	SaltsIBA 02/2005
1	SodiumIBA 02/2005
1	AntiemeticsIBA 01/2005
1	Silver Sulfadiazine (SSD)FDA LinkGeneric 01/2005
1	CeriumIBA 01/2005
1	OxalatesIBA 01/2005
1	Transferrin Receptors (Transferrin Receptor)IBA 01/2005
1	Local Anti-Infective Agents (Antiseptics)IBA 01/2005
1	cerium nitrateIBA 01/2005
1	major vault proteinIBA 01/2005
1	GalliumIBA 01/2003
1	imidazolium- bis(imidazole)dimethylsulfoxideimidazotetrachlororuthenate(III) (NAMI-A)IBA 01/2003
1	Platinum Compounds (Compounds, Platinum)IBA 01/2003
1	NucleotidesIBA 08/2001
1	imidazoleIBA 03/2001
1	Carboplatin (JM8)FDA LinkGeneric 01/2001

Therapy/Procedure

1	Therapeutics 01/2015
1	Drug Therapy (Chemotherapy) 06/2007
1	Investigational Therapies (Experimental Therapy) 02/2005